Recro Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>RP</div>
REPH -- USA Stock  

USD 3.25  0.30  8.45%

As many baby boomers are indifferent towards healthcare space, it makes sense to concentrate on Recro Pharma against current market trends. As we have suggested previously, Recro Pharma is beginning its drop as stockholders shift to be more bearish due to the increased sector volatility. The returns on investing in Recro Pharma and the market returns of the last few months appear not related. Fragile basic indicators of the company may also hint to signs of long-run losses for Recro stockholders. The next fiscal quarter end is expected on the 31st of December 2020. The stock goes through an active upward rally.
Published over a month ago
View all stories for Recro Pharma | View All Stories
Will Recro Pharma (NASDAQ:REPH) continue to drop in January?
The company's average rating is Strong Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Recro Pharma market sentiment investors' perception of the future value of Recro. Let us look at a few aspects of Recro technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Recro Pharma. In general, we focus on analyzing Recro Pharma stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Recro Pharma's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Recro Pharma's intrinsic value. In addition to deriving basic predictive indicators for Recro Pharma, we also check how macroeconomic factors affect Recro Pharma price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Recro Pharma's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Recro Pharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Recro Pharma. Your research has to be compared to or analyzed against Recro Pharma's peers to derive any actionable benefits. When done correctly, Recro Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Recro Pharma.

How does Recro Stands against Peers?

Analyzing Recro Pharma competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Recro Pharma across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Recro Pharma Competition Details

How Recro utilizes its cash?

To perform a cash flow analysis of Recro Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Recro Pharma is receiving and how much cash it distributes out in a given period. The Recro Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Recro Pharma Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at 18.66 Million

Payment of 1352 shares by Ryan Lake of Recro Pharma subject to Rule 16b-3

Legal trades by Recro Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Recro insider trading alert for payment of common stock by Ryan Lake, Chief Financial Officer, on 20th of January 2021. This event was filed by Recro Pharma Inc with SEC on 2021-01-20. Statement of changes in beneficial ownership - SEC Form 4. Ryan Lake currently serves as senior vice president - finance, chief accounting officer of Recro Pharma [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Recro Pharma Semi Deviation

Recro Pharma has current Semi Deviation of 3.64. Semi-deviation provides a good measure of downside risk for a equity or a portfolio. It is similar to standard deviation, but it only looks at periods where the returns are less than the target or average level.

Semi-deviation is the square root of semi-variance. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Deviation 
=  
SQRT(SV) 
 = 
3.64
SQRT = Square root notation
SV =   Recro Pharma semi variance of returns over selected period
Let's now compare Recro Pharma Semi Deviation to its closest peers:
REPH
TEVA
RDY
CASBF
TKPHF
REPH3.6446483484387304
TEVA2.18
RDY1.5
CASBF3.96
TKPHF2.25

Is Recro showing occurrence of lower volatility?

Semi deviation is down to 3.64. It may hint to a possible volatility drop. Recro Pharma shows above-average downside volatility for the selected time horizon. We advise investors to inspect Recro Pharma further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Recro Pharma future alpha.

The Current Takeaway on Recro Pharma Investment

While some companies in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Recro Pharma may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Recro valuation and our trade advice on Recro Pharma is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Recro Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Recro Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com